Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2019

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
(Amounts in thousands)
Sales of genetic tests
Panorama NIPT	$	37,556	$	35,999	$	111,269	$	104,981
HCS		26,149		23,565		73,184		63,248
Other genetic tests		3,231		3,098		10,946		9,055
Product revenues		66,936		62,662		195,399		177,284
Licensing and other
Constellation		1,251		1,054		3,895		3,652
Qiagen		—		—		675		—
BGI		6,844		—		11,862		—
Other		2,878		1,564		7,257		9,753
Licensing and other revenues		10,973		2,618		23,689		13,405
Total revenues	$	77,909	$	65,280	$	219,088	$	190,689

Schedule of disaggregation of revenue by payer types

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
(Amounts in thousands)
Insurance carriers	$	51,801	$	50,631	$	152,779	$	143,094
Laboratory partners		16,938		9,162		42,093		34,182
Patients		9,170		5,487		24,216		13,413
Total revenues	$	77,909	$	65,280	$	219,088	$	190,689

Schedule of total revenue by geographic area

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
(Amounts in thousands)
United States	$	64,839	$	58,651	$	187,515	$	165,646
Americas, excluding U.S.		806		932		2,391		2,629
Europe, Middle East, India, Africa		3,497		3,711		11,819		16,789
Other		8,767		1,986		17,363		5,625
Total revenues	$	77,909	$	65,280	$	219,088	$	190,689

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	September 30,		December 31,
(Amounts in thousands)	2019		2018
Assets:
Accounts receivable	$	58,905	$	62,223
Liabilities:
Deferred revenue, current portion	$	25,667	$	4,131
Deferred revenue, long-term portion		56,174		40,058
Total deferred revenues	$	81,841	$	44,189

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2018	$	44,189
Increase in deferred revenues		62,758
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(951)
Revenue recognized from performance obligations satisfied within the same period		(18,943)
Transferred in the sale of business		(5,212)
Balance at September 30, 2019	$	81,841

Schedule of current and long-term portions of deferred revenues

Deferred Revenues	Current		Long-term		Total
BGI agreement	$	12,049		16,050	$	28,099
Foundation Medical agreement		10,391		3,859		14,250
Qiagen agreement		2,305		36,265		38,570
Other deferred revenues		922	$	—		922
Balance at September 30, 2019	$	25,667	$	56,174	$	81,841